This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaffer, L. W. Articles by Siegl, P. K. Search for Related Content PubMed PubMed Citation Articles by Schaffer, L. W. Articles by Siegl, P. K.

Circulation, Vol 84, 1741-1748, Copyright © 1991 by American Heart Association

ARTICLES

Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis

LW Schaffer, JT Davidson, GP Vlasuk and PK Siegl
Department of Pharmacology, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.

BACKGROUND. Tick anticoagulant peptide is a specific, potent inhibitor of blood coagulation factor Xa. The effects of recombinant tick anticoagulant peptide (rTAP) and standard heparin (SH) were compared in an anesthetized baboon model of arterial thrombosis where platelet deposition onto a Dacron vascular graft segment of an arteriovenous (AV) shunt was studied. METHODS AND RESULTS. Animals were randomized to receive systemic administration of SH (10 or 100 U/kg i.v. bolus followed by 0.4 or 1.0 U/kg/min i.v. infusion, respectively) or rTAP (6.25, 12.5, or 25.0 micrograms/kg/min i.v. infusion). rTAP, but not SH, caused a significant (p less than 0.05), dose-dependent reduction of indium-111 labeled platelet and iodine-125 labeled fibrin (ogen) deposition onto the graft. Deposition was not significantly increased from baseline values during infusion of 12.5 or 25.0 micrograms/kg/min of rTAP. Blood flow was maintained at 64 +/- 9, 95 +/- 2, or 97 +/- 2% of baseline following infusion of 6.25, 12.5, or 25.0 micrograms/kg/min of rTAP, respectively. Both SH and rTAP significantly (p less than 0.05) decreased the systemic fibrinopeptide A (FPA) elevation during exposure to the Dacron graft. rTAP was fully antithrombotic at APTT values of 42.6 +/- 2.4 seconds (less than twofold basal value), while SH had no antithrombotic efficacy despite APTT values greater than 150 seconds (greater than fivefold basal value). CONCLUSIONS. The demonstrated antithrombotic effect of rTAP in the absence of alterations in primary hemostasis suggests that controlling thrombin generation through inhibition of factor Xa may be a novel and effective pharmacological approach in the prevention of high-shear arterial thrombosis.

This article has been cited by other articles:

				P. Stoll, N. Bassler, C. E. Hagemeyer, S. U. Eisenhardt, Y. C. Chen, R. Schmidt, M. Schwarz, I. Ahrens, Y. Katagiri, B. Pannen, et al. Targeting Ligand-Induced Binding Sites on GPIIb/IIIa via Single-Chain Antibody Allows Effective Anticoagulation Without Bleeding Time Prolongation Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1206 - 1212. [Abstract] [Full Text] [PDF]

				R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C Blood, April 15, 1998; 91(8): 2818 - 2829. [Abstract] [Full Text] [PDF]

				S. S. Rebello, H. S. Blank, W. E. Rote, G. P. Vlasuk, and B. R. Lucchesi Antithrombotic Efficacy of a Recombinant Nematode Anticoagulant Peptide (rNAP5) in Canine Models of Thrombosis after Single Subcutaneous Administration J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 91 - 99. [Abstract] [Full Text]

				B. Kaiser State-of-the-Art Review: Factor Xa Versus Factor IIa Inhibitors Clinical and Applied Thrombosis/Hemostasis, January 1, 1997; 3(1): 16 - 24. [Abstract] [PDF]

				R. S. Schwartz, D. J. Holder, D. R. Holmes Jr, J. P. Veinot, A. R. Camrud, M. A. Jorgenson, and R. G. Johnson Jr Neointimal Thickening After Severe Coronary Artery Injury Is Limited by Short-term Administration of a Factor Xa Inhibitor : Results in a Porcine Model Circulation, April 15, 1996; 93(8): 1542 - 1548. [Abstract] [Full Text]

				P. K. Shah New Antithrombotic Drugs for Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 165 - 176. [PDF]

				B. J. Biemond, P. W. Friederich, M. Levi, G. P. Vlasuk, H. R. Buller, and J. W. ten Cate Comparison of Sustained Antithrombotic Effects of Inhibitors of Thrombin and Factor Xa in Experimental Thrombosis Circulation, January 1, 1996; 93(1): 153 - 160. [Abstract] [Full Text]

				U. Orvim, R. M. Barstad, G. P. Vlasuk, and K. S. Sakariassen Effect of Selective Factor Xa Inhibition on Arterial Thrombus Formation Triggered by Tissue Factor/Factor VIIa or Collagen in an Ex Vivo Model of Shear-Dependent Human Thrombogenesis Arterioscler Thromb Vasc Biol, December 1, 1995; 15(12): 2188 - 2194. [Abstract] [Full Text]

				A. T. Gentile, T. G. DeLoughery, and J. M. Porter Novel Antithrombotic Agents in Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1994; 7(2): 57 - 72. [PDF]